Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterology 2022 March;68(1) > Minerva Gastroenterology 2022 March;68(1):69-76

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  EOSINOPHILIC ESOPHAGITIS: FROM PATHOPHYSIOLOGY TO MANAGEMENT 

Minerva Gastroenterology 2022 March;68(1):69-76

DOI: 10.23736/S2724-5985.21.02781-1

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Pharmacotherapies in eosinophilic esophagitis: state of the art

Elisa MARABOTTO 1 , Edoardo G. GIANNINI 1, Patrizia ZENTILIN 1, Sebastiano ZIOLA 1, Afscin DJAHANDIDEH SHEIJANI 1, Edoardo SAVARINO 2, Vincenzo SAVARINO 1

1 Gastrointestinal Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2 Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy



Eosinophilic esophagitis is a chronic immune-mediated esophageal disease with a Th2 inflammatory response to inhalant and food allergens that cause an eosinophilic infiltration of esophageal mucosa. The diagnosis requires an upper endoscopy with esophageal bioptic samples, in particular the number of eosinophils must be >15 eos/high power field. The main symptoms of EoE in adults are dysphagia and food impaction, and its incidence is growing. Nowadays, the etiology of EoE is not well understood and no standard therapy is available. Therefore, the aim of this review was to analyze the major studies present in literature regarding the various therapeutic approaches to this disease.


KEY WORDS: Eosinophilic esophagitis; Proton pump inhibitors; Steroids; Biologic products

inizio pagina